/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Transcode Therapeutics Inc share price today is $9.8, up 2.35%. The stock opened at $9.325 against the previous close of $9.575, with an intraday high of $9.39 and low of $9.325.

style

pb-0

Transcode Therapeutics Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$9.8 0.0235(2.35%) RNAZ at 13 Mar 2026 03:03 PM Biotechnology

Lowest Today 9.325

Highest Today 9.39

Today’s Open 9.325

Prev. Close 9.575

52 Week High 46.76

52 Week Low 6.08

Day’s Range: Low 9.325 High 9.39

52-Week Range: Low 6.08 High 46.76

Transcode Therapeutics Inc Institutional Holdings

Transcode Therapeutics Inc Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Transcode Therapeutics Inc Fundamentals

Market Cap 8.78 M

PB Ratio 6.1572

PE Ratio 0.0

Enterprise Value 3.01 M

Total Assets 7.29 M

Volume 16152

Transcode Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-19592604 -19.6M, FY22:-35129936 -35.1M, FY21:-6938469 -6.9M, FY20:-2738330 -2.7M, FY19:-764143 -0.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-4781 -0.0M, Q2/2025:-13443 -0.0M, Q1/2025:-51174 -0.1M, Q3/2024:null 0.0M, Q2/2024:-142835 -0.1M

Quarterly Net worth Q3/2025:-4856051 -4.9M, Q2/2025:-4276502 -4.3M, Q1/2025:-12085413 -12.1M, Q3/2024:-2321387 -2.3M, Q2/2024:-5190814 -5.2M

About Transcode Therapeutics Inc & investment objective

Company Information TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Organisation Biotechnology

Employees 7

Industry Biotechnology

CEO Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*